Teewinot Life Sciences

Teewinot Life Sciences is an international biopharmaceutical company employing its patent-protected CannSynthesis® technology to biosynthesize cannabinoids for the large-scale manufacture of pharmaceutically pure cannabinoids including the varin series of compounds, which are only found in relatively small quantities in the cannabis plant. Teewinot’s focus is on the biosynthetic production of pure, naturally-occurring cannabinoids, cannabinoid prodrugs and analog compounds by utilizing proprietary biocatalysis and synthetic biology for clinical development of FDA-approved pharmaceuticals. To date, Teewinot researchers have synthesized over 18 different naturally occurring cannabinoids in pharmaceutically pure form. The company employs its proprietary, disruptive technology to develop therapeutics for diseases identified as viable cannabinoid targets such as pain management, opioid addiction, oncology, psychiatric and central nervous system disorders, inflammation, and other drug development indications. Headquartered in Tampa, Florida, Teewinot is a global leader in the manufacturing and delivery of safe and standardized products containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs for diverse consumer markets. The company’s wholly owned subsidiaries in Ireland and Canada, along with collaborations formed with key research institutions, consumer product companies, manufacturers, and local communities, combine cutting-edge scientific research on cannabinoids with an aggressive intellectual property portfolio to create new and improved patient therapies.

Teewinot Laboratories (“TLABS”) is the center of all research for the company, operating Health Canada federally-licensed laboratories in both Vancouver, British Columbia, and Steinbach, Manitoba. The Vancouver laboratory has primary expertise in genomics, synthetic biology, organic chemistry, and molecular biology. It also provides services focused on the scaling and refinement of biosynthetic processes and outputs. The Steinbach laboratory provides services focused on formulation technologies, plant breeding (genetic development and engineering), and research analytics.

Teewinot Technologies Ltd. (“TTECH”), located in Dublin, Ireland, serves as the Intellectual Property repository and global patient filer for the Teewinot Life Sciences Group. TTECH is responsible for all IP management and is the contracted party for all licensing agreements. TTECH also services the company’s global regulatory oversight group and provides accounting and audit services to the Teewinot family of companies.

Teewinot has licensed its CannSynthesis® technology for the commercial production of the first analytical standard of CBCA (cannabichromenic acid) and for the manufacture of a patient-protected prodrug of a cannabinoid. A prodrug is a molecule that after administration is metabolized into a pharmacologically active drug. Teewinot’s cannabinoid prodrugs are designed to be more bioavailable and stable in the human body, thereby increasing their efficacy. Since the majority of cannabinoids are produced in very small quantities in the cannabis plant and are expensive to chemically synthesize, most cannabinoids have not been available for research and therapeutic applications. That has now changed with the development and commercial introduction of Teewinot’s revolutionary technologies for the manufacture and formulation of cannabinoids in kilogram quantities. Teewinot’s CannSynthesis® technology is able to take cannabinoid pharmaceuticals from theory to reality, facilitating regulatory compliance with its ability to deliver consistent and controlled dosages. Through its partnerships with leading universities and pharmaceutical companies, Teewinot is working to move the development of these proprietary compounds into clinics to provide novel patient therapies.

Teewinot enjoys commercial first-mover advantage in the field of cannabinoid biosynthesis with patents covering biosynthetic processes and equipment for the manufacture of cannabinoids, as well as water-soluble cannabinoid formulation technology. Teewinot’s disciplined approach to research and development targets specific applications, which allows for customized product solutions and formulation challenges. Teewinot is available to assist commercial partners in the development or manufacture of new cannabinoid-based pharmaceuticals, prodrugs or analogs. For the first time, licensees will be able to manufacture commercial quantities of naturally-occurring cannabinoids and cannabinoid prodrugs that does not involve growing the cannabis plant or expensive chemical synthesis. Regulations and emerging technologies create significant impacts on the entire cannabis-related industry and companies that focus on cannabinoids provide investors with a rewarding path forward.

Teewinot has assembled a veteran management team with demonstrated success in leadership, growth, pharmaceutical development, marketing and aftermarket support. The organization includes a team of highly experienced scientists, business people, attorneys and other support personnel who are carefully aligning the intellectual property strategy with business goals and scientific developments. Teewinot President, Director and CEO Jeffrey M. Korentur is a co-founder of the company with more than 25 years of experience in leadership position in military and private sector roles. He is joined by Richard Peet, J.D., Ph.D., who serves as the chief intellectual property counsel; Bryan K. Brink, vice president of finance; Dr. Malcolm Kavarana, chief scientific officer and senior director intellectual property; and Eric A. Walker as chief information officer.

Teewinot’s strengths lie in its commitment to innovative research that unlocks the medicinal properties found within the cannabis plant, its disciplined approach to research and development with targeted applications, and its determination to connect and collaborate with research institutions, consumer product companies, manufacturers, local communities, and team members. Teewinot’s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid-based medicines and therapies.

Investment Considerations
  • Holds 7 U.S. patents covering biosynthesis of cannabinoids, including first U.S. issued patent to create water-soluble cannabinoids
  • Aggressively seeking intellectual property patent protection in key countries worldwide
  • Able to manufacture kilogram quantities of 18 naturally occurring cannabinoids through biosynthetic processes called CannSynthesis®
  • Canadian subsidiary holds controlled substances license from Health Canada
Additional Resources

twitter

Company News & Data

News & Media Overview Chart Financials Filings Time & Sales Historical Data

Contact us: 212.418.1217